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Volume 52, Number 2 Abstracts 527Conclusions: Physicians with limited TEVAR experience who under-
went simulation-assisted training prior to initial TEVAR performance had
significantly fewer total number of complications than experienced physi-
cians who did not undergo simulation training, mostly due to a significant
reduction in deployment-related complications (type I endoleaks) and
stroke incidence.
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Objectives:Controversy exists as to whether the brachiobasilic arterio-
venous fistula (BBAVF) should be performed in one or two stages. We
compare primary failure rates, as well as primary and secondary patency rates,
of one- and two-stage BBAVF.
Methods: Patients undergoing one- and two-stage BBAVF at two
institutions were compared retrospectively with respect to age, sex, body
mass index, use of preoperative venous duplex ultrasound, diabetes, hyper-
tension, and causes of end-stage renal disease. Categoric variables were
compared using 2 and Fisher exact test. The Wilcoxon rank sum test was
used to compare continuous variables. Primary and secondary patency rates
were assessed using Kaplan-Meier survival analysis and the Cox proportional
hazards model.
Results: The study identified 90 patients (60 one-stage and 30 two-
stage). Mean follow-up was 14.2 months, and the mean time interval
between the first and second stage was 11.2 weeks. Three patients in each
group required procedures to maintain assisted primary patency. Although
no significant difference in early failure existed (one-stage, 22.9% vs two-
stage, 9.1%, P  .2), the two-stage BBAVF showed significantly improved
primary patency (hazard ratio, 0.31; 95% CI, 0.09-0.99; P  .048) and
significantly improved secondary patency (hazard ratio, 0.18; 95% CI,
0.04-0.84; P  .03). Mean primary patency for one stage BBAVF was 72.3
weeks and two-stage was 138 weeks (1 SD; P  .05). Mean secondary
patency was 94 weeks and 139 weeks, respectively (1 SD; P .05). Primary
patency at 1 year for one- and two-stage stage BBAVF was 78% and 84%,
respectively (P  .05). Functional primary patency at 1 year for one- and
two-stage BBAVF was 61% and 88%, respectively (P  .05). Complication
rates were not statistically different (each greater than P  .11).
Conclusions: Patency rates appear to be improved with the two-stage
BBAVF. There is no difference in the complication rate. Optimal surgical
techniques for patients undergoing BBAVF for dialysis are discussed. Longer-
lasting hemodialysis access improves patient outcome and decreases morbid-
ity associated with dialysis.
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Background: The National Kidney Foundation-Kidney Disease Out-
comes Quality Initiative (KDOQI) for Vascular Access guidelines state that
late-stage chronic kidney disease (CKD) patients should undergo native
arteriovenous fistula (AVF) creation at least 6 months before the anticipated
start of hemodialysis (HD) treatments to obviate the need for other vascular
access types. The objective was to determine the incidence of HD, the
functional patency, and associated morbidity of AVFs in late-stage CKD
patients placed according to KDOQI.
Methods: Consecutive patients with late-stage CKD who underwent
“first-time” index AVF creation using K/DOQI guidelines for anatomy
between January 2003 and December 2007 at three tertiary academic
centers were retrospectively evaluated. Baseline demographics, index AVF
type, and clinical comorbidities were recorded. Patients were stratified into
one of four groups (A-D) over the follow-up course based on the patency of
their index AVF and whether or not they began HD. The ideal primary
outcome was AVF maturation and use for HD (group A; cumulative
functional patency). Other outcomes included AVF patency but no HD
(group B), HD with AVF failure (group C), or no HD and AVF abandon-
ment (group D). Secondary end points were time to first cannulation,
complications, and secondary interventions.
Results: Index AVFs were created (46% forearm and 54% upper arm) in
150 CKD patients (85% male; median age, 63 years). At a median follow-up
of 10 months, 74 patients (49%) were receiving HD and 48 (65%) were
using their index AVF (group A), while 26 (35%) were not (group C).
Thirty-four patients (23%) never initiated HD treatments, but had a viable
AVF. AVF abandonment was 51%. Mean maturation time of all index AVFs
that were cannulated was 285 days (range, 30-1265 days). Complications
encountered were maturation failure for cannulation (15%), focal stenosisrequiring intervention (13%), inadequate flows on HD (9%), steal syndrome
(9%), and thrombosis (8%). Cumulative functional patency for all index
AVFs was 19% at 6 months and 27% at 12 months, with a mean number of
two interventions per AVF (range, 1-10). Mortality for the group during the
study was 23%.
Conclusion: AVF creation in late-stage CKD patients has sobering
results. This calls into question the wisdom of early AVF planning in this
population.
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Objective: Many vascular surgeons construct arteriovenous fistula
(AVF) for hemodialysis access as the primary choice access. However, a
significant number of AVF fail to mature, leading to patient frustration and
repeated operations. MMP activity, particularly MMP-2 and MMP-9, are
considered important for AVF maturation. We therefore sought to identify
whether serum MMPs could serve as a biomarker for predicting future
successful AVF maturation.
Methods:Blood was collected at the time of surgery from patients with
chronic renal insufficiency requiring long-term access. Serum was separated
from whole blood by the use of an ultracentrifuge at 1000g for 10 minutes.
Serum aliquots were frozen at –80°C until used for analysis. MMP-2,Fig.
